The stock price of Altamira Therapeutics (NASDAQ: CYTO) skyrocketed over 100% with Friday’s market open, after the announcement of positive efficacy in its’ much anticipated Bentrio nasal spray in vitro against the Delta variant of Covid-19.
The drug-free nasal spray protects against airborne viruses and allergens and has previously been shown to be effective against the Alpha variant.
Thomas Meyer, Altamira Therapeutic's founder, Chairman and CEO expressed his confidence:
“These fresh results provide further support for the broad applicability of Bentrio. By forming a protective film on the nasal mucosa and trapping particles, Bentrio has a purely physical mode of action and is thus suitable for use across different types of viruses and virus variants. We look forward to continuing the commercial rollout of the product, making it available to all those seeking protection.”
The next stage in assuring Bentrio’s efficacy and safety comes with the success of a Covid-19 clinical trial – which the company is still awaiting approval for by the Drugs Controller General of India.
Following today’s stock surge, Altamira is showing a 251% gain as of this time last year, with a daily rally of 98%. Investors should look out for news on the upcoming clinical trial for further confirmation of a buy.
